Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.
about
Treatment of cerebellar ataxia.Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.A family with hereditary cerebellar ataxia finally confirmed as Gerstmann-Straussler-Scheinker syndrome with P102L mutation in PRNP gene.In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
P2860
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Assessing the efficacy of spec ...... spinocerebellar ataxia type 1.
@en
Assessing the efficacy of spec ...... spinocerebellar ataxia type 1.
@nl
type
label
Assessing the efficacy of spec ...... spinocerebellar ataxia type 1.
@en
Assessing the efficacy of spec ...... spinocerebellar ataxia type 1.
@nl
prefLabel
Assessing the efficacy of spec ...... spinocerebellar ataxia type 1.
@en
Assessing the efficacy of spec ...... spinocerebellar ataxia type 1.
@nl
P2093
P2860
P1433
P1476
Assessing the efficacy of spec ...... spinocerebellar ataxia type 1.
@en
P2093
Elsdon Storey
Volga Tarlac
P2860
P2888
P356
10.1007/S12311-012-0399-X
P577
2013-02-01T00:00:00Z